Emily Curran, MD
CML | MDS/MPN | Lymphoma | AML/ALL | CLL | Blood Cancer | Myeloma | Other
Phase 1
A Study of LP-118 in Patients With Advanced Tumors
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects. The study has a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b). Secondary objectives of the study are to evaluate preliminary efficacy regarding the effect of LP-118 on objective response rate (ORR) using disease specific response criteria, progression-free survival (PFS), and duration of response (DOR), and overall survival (OS) in adult subjects with relapsed/refractory blood cancers.
This study may be appropriate for those with: Relapsed / Refractory Cancer